OMEX vs. CYCC

In the year-to-date period, OMEX achieves a 8.57% return, which is significantly higher than CYCC's -71.98% return. Over the past 10 years, OMEX has outperformed CYCC with an annualized return of -19.14%, while CYCC has yielded a comparatively lower -63.64% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Odyssey Marine Exploration, Inc. (OMEX) and Cyclacel Pharmaceuticals, Inc. (CYCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current OMEX Sharpe Ratio is -0.30, which is higher than the CYCC Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of OMEX and CYCC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

OMEX has not paid dividends to shareholders, while CYCC's dividend yield for the trailing twelve months is around 9.20%.

The maximum OMEX drawdown since its inception was -99.70%, roughly equal to the maximum CYCC drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for OMEX and CYCC.

The current volatility for Odyssey Marine Exploration, Inc. (OMEX) is 32.33%, while Cyclacel Pharmaceuticals, Inc. (CYCC) has a volatility of 51.54%. This indicates that OMEX experiences smaller price fluctuations and is considered to be less risky than CYCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Odyssey Marine Exploration, Inc. and Cyclacel Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.